Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Q3-2021 Dermatology Update

Skip to the end of the Expertise Menu

Q3-2021 Dermatology Update

The dermatology space continues to see consistent transaction volume, characterized by strategic bolt-ons for platforms looking to build density and expand their reach. While new platform formations have been relatively scarce over the last two years, Provident expects larger sponsors to enter the space through investment in a number of private equity backed MSOs that are currently out to market. There is another cohort or tier of private equity firms with a thesis in the dermatology sector that are looking to put investment capital to work. Provident expects those sponsors to compete with some of the larger, existing PE-backed platforms for secondary deals that are currently out to market. With at least a handful of private equity firms exploring a sale of their respective dermatology platforms, Provident expects the next two quarters to be particularly active as some of those platforms look to grow via acquisition prior to a sale.

To print and download the full Dermatology Update report, please click below…

[holo_button icon=”/wp-content/uploads/2021/10/Q3-2021-Dermatology-Newsletter.pdf” link=”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]

 

Sources: SEC Filings; Company Press Releases, and Reports; IBISWorld; Capital IQ; PHP Estimates and Research. This document has been compiled with publicly available information. Provident Healthcare Partners, LLC makes no guarantee of its accuracy or completeness. No data or statement should be construed to be a recommendation for the purchase, sale, or retention of any security.